Pulmonary Artery Involvement in Takayasu's Arteritis

Takayasu Arteritis Clinical Trial

Official title:

Pulmonary Artery Involvement in Takayasu's Arteritis: a Retrospective Study in China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03189602
• Other study ID #: PUMCH-Pulmonary arteritis
• Status: Completed
• Phase: N/A
• First received: June 15, 2017
• Last updated: June 15, 2017
• Start date: January 1, 2014
• Est. completion date: December 31, 2015

Study information

• Verified date: June 2017
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of PA involvement in TA patients.

Description:

Takayasu's arteritis patients with pulmonary artery involvement were enrolled into this study. The demographic information of the patients (age, sex, course of disease), symptoms at their admissions (cough, hemoptysis, dyspnea, palpitations, fever), laboratory examinations (blood lab routines, erythrocyte sedimentation rate, C-reactive protein), and imaging examinations (vascular ultrasonography, computed tomographic angiography, echocardiography, chest CT, CTPA, pulmonary perfusion imaging, pulmonary angiography, PET/CT) were collected by reviewing the cases. The prognostic information was collected by telephone follow-up. The follow-up end point was December 2015.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: December 31, 2015
• Est. primary completion date: December 31, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 67 Years

Eligibility

Inclusion Criteria:

• 1.Meet the diagnostic criteria of TA as defined by the American College of Rheumatology (ACR).

• 2.PA involvement: meet at least one of three items: (1) at least one of computed tomographic pulmonary angiography (CTPA), pulmonary perfusion imaging, or pulmonary arteriography suggests thickening of vessel wall, stenosis, aneurysm, or occlusion; (2) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) suggests high intake of local radioactive material in pulmonary artery wall; (3) pulmonary artery systolic blood pressure is higher than 50 mmHg assessed by transthoracic echocardiography (defined as PAH), without left ventricular disease.

Exclusion Criteria:

Related Conditions & MeSH terms

• Arteritis
• Hypertension
• Hypertension, Pulmonary
• Pulmonary Artery Hypertension
• Takayasu Arteritis

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulmonary Artery Systolic Blood Pressure	Pulmonary artery systolic blood pressure(PASP) assessed by transthoracic echocardiography when admission. PASP>50mmHg is defined as pulmonary hypertension.	1day